These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453 [No Abstract] [Full Text] [Related]
5. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer. Fu G; Chazen RS; MacMillan C; Witterick IJ JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552 [TBL] [Abstract][Full Text] [Related]
6. Preoperative Risk Stratification of Follicular-patterned Thyroid Lesions on Core Needle Biopsy by Histologic Subtyping and RAS Variant-specific Immunohistochemistry. Kim M; Jeon S; Jung CK Endocr Pathol; 2023 Jun; 34(2):247-256. PubMed ID: 37040004 [TBL] [Abstract][Full Text] [Related]
7. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations. Paulson VA; Shivdasani P; Angell TE; Cibas ES; Krane JF; Lindeman NI; Alexander EK; Barletta JA Thyroid; 2017 Apr; 27(4):506-511. PubMed ID: 28114855 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population. Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113 [TBL] [Abstract][Full Text] [Related]
9. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series. Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345 [TBL] [Abstract][Full Text] [Related]
10. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea. Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of NRAS(Q61R) protein in follicular-patterned thyroid tumors. Oishi N; Kondo T; Vuong HG; Nakazawa T; Mochizuki K; Kasai K; Inoue T; Tahara I; Hirokawa M; Miyauchi A; Katoh R Hum Pathol; 2016 Jul; 53():51-7. PubMed ID: 26980032 [TBL] [Abstract][Full Text] [Related]
12. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules. Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276 [TBL] [Abstract][Full Text] [Related]
13. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma. Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715 [TBL] [Abstract][Full Text] [Related]
14. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659 [TBL] [Abstract][Full Text] [Related]
15. Detection of RAS mutation by pyrosequencing in thyroid cytology samples. Guerra A; Carrano M; Angrisani E; Puzziello A; Izzo G; Di Crescenzo V; Vatrella A; Vitale M Int J Surg; 2014; 12 Suppl 1():S91-4. PubMed ID: 24866065 [TBL] [Abstract][Full Text] [Related]
16. Preoperative detection of RAS mutation may guide extent of thyroidectomy. Patel SG; Carty SE; McCoy KL; Ohori NP; LeBeau SO; Seethala RR; Nikiforova MN; Nikiforov YE; Yip L Surgery; 2017 Jan; 161(1):168-175. PubMed ID: 27863786 [TBL] [Abstract][Full Text] [Related]
17. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288 [TBL] [Abstract][Full Text] [Related]
18. ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW. Nikiforov YE Endocr Pract; 2017 Aug; 23(8):979-988. PubMed ID: 28534687 [TBL] [Abstract][Full Text] [Related]
19. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth. Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677 [TBL] [Abstract][Full Text] [Related]
20. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma. An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]